Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

Theranexus announces appointment of Jérôme Martinez to its Board of Directors
13/12/2018
Download PDF File (370 Ko)

Theranexus September 30th cash position and business update
09/11/2018
Download PDF File (369 Ko)

Theranexus announces inclusion of last patient in phase II trial of drug candidate THN102 on narcolepsy patients

29/10/2018
Download PDF File (371 Ko)

Theranexus plans to extend its phase 2 pipeline with a third program

15/10/2018
Download PDF File (382 Ko)

Theranexus announces that Rodolphe Besserve will join its Board of Directors

11/10/2018
Download PDF File (368 Ko)

Theranexus announces a new European patent protecting THN201, its drug candidate for the treatment of neurocognitive disorders including those associated with Alzheimers

09/10/2018
Download PDF File (373 Ko)

 Recognition of the scientific excellence of Theranexus

01/10/2018
Download PDF File (379 Ko)

Theranexus announces its first half 2018 results

27/09/2018
Download PDF File (335 Ko)

Theranexus obtains the authorization to start a Phase 1b clinical trial with its drug candidate THN201 in neurocognitive disorders due to Alzheimer's disease

26/09/2018
Download PDF file (384 Ko)

Theranexus announces the inclusion of the first patient in its phase 2 clinical trial evaluating its drug candidate THN102 in excessive daytime sleepiness (EDS) in patients with Parkinson's disease

16/07/2018
Download the PDF file (397 Ko)